Report under the *Fighting Against Forced Labour and Child Labour in Supply Chain Act* for the year ended December 31, 2023

INTRODUCTION

This report has been prepared by AbCellera Biologics Inc. ("AbCellera" or the "Company") under *Canada's Fighting Against Forced Labour and Child Labour in Supply Chains Act* (the "Act") for our financial year ended December 31, 2023 for the Government of Canada.

AbCellera qualifies as an entity required to file this Report under the Act because AbCellera imports goods produced outside of Canada, is a corporation that has a place of business in Canada, and that, based on its consolidated financial statements, meets at least two of the conditions for at least one of its two most recent financial years.

AbCellera is committed to promoting labour practices that protect workers' safety and human rights, including preventing and mitigating the risk of forced labour and child labour in our operations and supply chains.

STRUCTURE, ACTIVITIES, AND SUPPLY CHAIN

AbCellera discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating with partners on innovative drug development programs.

The Company is a corporation publicly traded on the Nasdaq (ABCL). AbCellera is headquartered in Vancouver, Canada, with locations in Montreal, Canada; Boston, United States; and Sydney, Australia.

The Company's annual report, available on its investor relations site, provides more information on the organizational structure and business activities.

As a drug discovery and development company, AbCellera's supply chain includes goods that are imported from outside of Canada. Examples of the goods we procure include lab equipment, personal protective equipment, laboratory supplies, office supplies, equipment parts for use in day-to-day operations. We engage contractors and consultants to deliver legal, accounting, security, janitorial, and general services to support our operations in low risk jurisdictions.

STEPS TO PREVENT AND REDUCE THE RISKS OF FORCED LABOUR AND CHILD LABOUR

In 2023, AbCellera took the following steps to prevent and reduce the risks of forced labour or child labour in our operations and supply chain:

- We rely on our existing grievance mechanisms to ensure that complaints or concerns relating to human rights were heard and comprehensively addressed; and
- Established and communicated procurement guidelines that support team members to be cognizant of the social rights extended to all people with respect to labour standards and part of the decision making process on the procurement of goods.

GOVERNMENT REGULATIONS, POLICIES AND DUE DILIGENCE PROCESSES

Government regulations

Our focus is on the discovery of antibodies that our partners use to improve the speed and success of their antibody discovery efforts; however, for 2023, the Company was not involved in antibody discovery, did not manufacture any products, and did not conduct clinical trials. As such, while we are subject to several regulations, such as those governing our laboratory facilities and those that apply to businesses in the private sector generally, we are not subject to many of the types of regulations that ordinarily apply to companies in the life sciences, biotechnology, and pharmaceutical sectors and industries.

However, AbCellera believes that the long-term success of our business depends, in part, on our partners' ability to develop and sell products using the antibodies that we discover. Therefore, the Company believes that the regulations governing our pharmaceutical and biotechnology partners have the most significant impact on the business.

Government authorities at the federal, state, and local level in the United States, as well as in the European Union and other countries and jurisdictions, extensively regulate the research, development, testing, manufacturing, quality control, approval, labelling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of pharmaceutical products, including biological products such as those our partners develop. The processes for obtaining marketing approvals in the United States and other foreign countries and jurisdictions, along with subsequent compliance with applicable statutes, regulations and other regulatory authorities, requires substantial time and financial resources.

Our partners are subject to various regulations in applicable jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of their products. Regardless of whether our partners obtain approval from the U.S. Food and Drug Administration or the European Commission for a product, they must also obtain the requisite approvals from regulatory authorities in individual countries before the commencement of clinical studies or marketing of the product in those countries.

Policies

AbCellera has a "Code of Business Conduct and Ethics" (the "Code") which applies to AbCellera's directors, officers, employees, and other personnel that AbCellera may determine should be subject to the Code, such as contractors or consultants. The Code sets our basic requirements for business conduct and expected behaviours, and is designed to promote integrity and deter wrongdoing. AbCellera expects its personnel to adhere to the highest ethical standards and uphold corporate values. The Code requires its personnel to follow applicable laws, rules and regulations, and to not engage in any type of illegal, unethical, fraudulent, or corrupt business practices. The Code is reviewed annually.

Due diligence processes

The Company did not conduct any due diligence for forced labour or child labour as we have not assessed any risks related to our supply chain.

The Company's senior management team are accountable for overseeing and managing the due diligence processes, with the Finance, Procurement, and Legal teams implementing the programs to reduce the risk of forced labour or child labour in the supply chain. This year, the Company and senior management will make efforts to assess, identify and implement mitigation measures related to forced labour and child labour.

Assessing the risk of forced labour and child labour

To date, we have not done a risk assessment and will complete a risk assessment for 2024. AbCellera does recognizes that the risk of forced labour and child labour increases when operating in or procuring goods from locations with minimal legal protections for workers or high levels of poverty, inequality, political instability, and unemployment.

REMEDIATION MEASURES AND REMEDIATION OF LOSS OF INCOME

AbCellera's approach to remediation is set out in the Code. We encourage the reporting and investigation of human rights violations. The Company does not tolerate direct or indirect acts or retaliation made in response to a good faith report.

To date, AbCellera has not received any complaints relating to forced labour or child labour in our operations or supply chain and has not taken any remediation measures or remedied the loss of income to families as a result of forced labour or child labour.

EMPLOYEE TRAINING

AbCellera does not currently provide training to its personnel specifically related to forced labour or child labour. In 2024, AbCellera's procurement team plans to develop and provide training addressing the risks of forced and child labour. The Company will assess opportunities for future employee training.

ASSESSING EFFECTIVENESS

At the end of 2023, the Company did not have an assessment mechanism for forced and child labour.

APPROVAL AND ATTESTATION

In accordance with the requirements of the Act and, in particular, section 11(4)(b)(i) of the Act thereof, I attest that I have reviewed the information contained in the report for the entity or entities listed above. Based on my knowledge and experience, I attest that the information in the report is true, accurate, and complete in all material respects for the Act for the reporting year listed above.

Dated in Vancouver, British Columbia, this 31st day of May 2024.

Carl Hansen, PhD
Chairman, CEO & President